FDAnews
www.fdanews.com/articles/208326-euroimmun-gets-ce-marks-for-two-covid-19-assays

Euroimmun Gets CE Marks for Two COVID-19 Assays

June 23, 2022

PerkinElmer subsidiary Euroimmun has received CE marks for two COVID-19 assays — the Anti-SARS-CoV-2 Omicron ELISA (IgG) and Anti-SARS-CoV-2 RBD ChLIA (IgG) tests.

The Anti-SARS-CoV-2 Omicron ELISA (IgG) test is an enzyme-linked immunosorbent assay that targets the spike protein of the SARS-CoV-2 Omicron variant and can quantify IgG antibodies formed against the variant.

Anti-SARS-CoV-2 RBD ChLIA (IgG) is a chemiluminescent immunoassay that also measures IgG antibodies against the virus.

Both test systems are now available to laboratories in countries that accept the CE mark, the company said.

View today's stories